To the full analysis
Eurofins Scientific stock: growth
ERF.PAEurofins Scientific reported $8.08B in revenue for fiscal 2025, up 5% on the prior year, up 6.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
17%
per year from 2006 to 2025, per share 15.4%
Earnings (Annual rate)
19%
per year from 2006 to 2025, per share 17.2%
Free cash flow (Annual rate)
28.6%
per year from 2006 to 2025, per share 26.8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 6.1% | 14.1% | 17.0% |
| Revenue per share | 6.8% | 12.3% | 15.4% |
| Earnings | −2.5% | 18.5% | 19.0% |
| Earnings per share | −1.9% | 16.6% | 17.2% |
| Free cash flow | −9.2% | 15.9% | 28.6% |
| Free cash flow per share | −8.6% | 14.1% | 26.8% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $407.77M | $19.4M | $4.99M |
| 2007 | $544.93M | $19.54M | −$9.41M |
| 2008 | $701.16M | $19.62M | $5.81M |
| 2009 | $709.26M | −$12.5M | $20.72M |
| 2010 | $753.88M | $25.93M | $48.69M |
| 2011 | $918.54M | $61.4M | $62.51M |
| 2012 | $1.16B | $73.05M | $69.28M |
| 2013 | $1.36B | $79.98M | $77.33M |
| 2014 | $1.56B | $87.66M | $86.04M |
| 2015 | $2.16B | $96.75M | $135.21M |
| 2016 | $2.81B | $192.81M | $190.78M |
| 2017 | $3.29B | $240.2M | $176.62M |
| 2018 | $4.19B | $248.1M | $198.84M |
| 2019 | $5.06B | $216.3M | $442.91M |
| 2020 | $6.03B | $597.71M | $961.83M |
| 2021 | $7.44B | $867.2M | $1.1B |
| 2022 | $7.44B | $676.16M | $527.57M |
| 2023 | $7.22B | $343.84M | $518.37M |
| 2024 | $7.7B | $450.33M | $875.95M |
| 2025 | $8.08B | $526.35M | $592.83M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Jun 2022)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.